ArticleCancer science2026

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors.

Kinnosuke Matsumoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.